Wednesday, June 19, 2019
TherapeuticsMD (TXMD)
What Investors are Missing
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- The stock slides. TXMD shares are down 15% since the company held its analyst day on June 10, 2019. We believe that the shares overreacted to management’s weak revenue outlook which anticipates 87% revenue growth for the full year 2019 (21% below consensus revenue expectations). We estimate that revenues will show an accelerated growth in subsequent years, up 180% in 2020, up 346% in 2021 and up 108% in 2022.
- The bigger picture. We believe that there are encouraging revenue attributes; 1) the company’s product, Imvexxy, had solid upward Q1 revenue trajectory, surpassing…
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.